127. 前頭側頭葉変性症 Frontotemporal lobar degeneration Clinical trials / Disease details
臨床試験数 : 90 / 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04993755 (ClinicalTrials.gov) | October 1, 2021 | 19/7/2021 | A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD | A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD) | Amyotrophic Lateral Sclerosis;Frontotemporal Dementia | Drug: TPN-101, 400 mg/day;Drug: Placebo | Transposon Therapeutics, Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 42 | Phase 2 | United States;Belgium;France;Germany;Spain;Netherlands |